Share

    


In This Section

Our Partners

ASCP: Stronger Together

Society of Interventional Oncology (SIO)

The France Foundation

In partnership with American Society for Clinical Pathology (ASCP), Society of Interventional Oncology (SIO), and The France Foundation (TFF).

Our Supporters

This project is supported by an educational grant from AstraZeneca.

Home / Learn / Cancer Types / Gastrointestinal Cancer / Liver Cancer / HCC Education and Protocols to Advance Treatment through Integrated Collaboration

HCC Education and Protocols to Advance Treatment through Integrated Collaboration

There are numerous challenges for clinicians who manage patients with hepatocellular cancer (HCC). This includes diagnosing and staging patients in a timely manner while staying abreast with the latest clinical advances in the field. The Association of Community Cancer Centers (ACCC)—in partnership with the American Society for Clinical Pathology (ASCP), the Society of Interventional Oncology (SIO) and the France Foundation (TFF), —is committed to ensuring providers are equipped with the knowledge needed to develop practical protocols to inform personalized treatment options for HCC patients.

The goal of this initiative is to provide the latest clinical information to increase clinicians’ knowledge and improve their competence confidence in providing the most accurate recommendations for treatment as members of the multidisciplinary HCC cancer treatment team.

Content includes the clinical profiles of current and emerging immunotherapy agents as well as the use of these agents in combination, in succession, and sequentially with interventional arterially directed therapy (ADT).

Participants will actively engage in interactive small-group activities, including:

  • A multidisciplinary HCC tumor board panel
  • Breakout sessions delving into tissue sample issues, and treatment options for early, intermediate, and advanced HCC
  • Patient counseling and shared decision-making

Learning Objectives

Upon completion of the activity, participants should be able to:

  • Apply strategies for early and accurate diagnosis of HCC stages
  • Summarize MOA and clinical profiles of new and emerging IO agents (mono and combo) for each stage of HCC
  • Analyze data on IO therapy with ADT procedures to identify appropriate patients
  • Describe the role of HCC care team members and explain techniques to increase communication and collaboration
  • Formulate a plan for discussions with patients around their care plans

Dates and Locations

Houston, TX   San Diego, CA  New York, NY 
March 2, 2023  March, 2023 May, 2023

Register Now

This activity is jointly provided by The France Foundation, Society of Interventional Oncology, American Society for Clinical Pathology, and Association of Community Cancer Centers.

This activity will award AMA PRA Category 1 Credit(s)™ and nursing contact hours.

For additional CE information, please visit tffevents.com/hcc.